Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Drugs

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

New Agent Reduces Risk of Diabetic Retinopathy Posted: Friday, June 23, 2006

A protein kinase C-beta inhibitor reduced the risk of sustained vision loss and progression of diabetic macular edema in two phase III trials, researchers announced.

New Drug Galvus Lowers A1c 2.8% Posted: Friday, June 23, 2006

Galvus, a new once-daily oral treatment option for type 2 diabetes, lowers A1c 2.8% and demonstrates impressive efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients.

Pfizer, Bayer Partner on Fat Modifier Obesity Drugs Posted: Friday, June 23, 2006

Pfizer is buying exclusive worldwide rights to an experimental class of Bayer obesity drugs.

Investigational Januvia (MSD) Put Through Its Paces for Diabetes Posted: Thursday, June 15, 2006

Researchers reported that, Januvia (sitagliptin), an investigational oral agent for type 2 diabetes, appears to be effective when given as a monotherapy or as an adjunct to Glucophage (metformin) or Actos (pioglitazone). FDA approval expected soon.

New Oral Insulin Shows Safety, Feasibility in Trials Posted: Thursday, June 15, 2006

In the first human trials of oral insulin, the drug acted within 15 minutes and showed 60%-70% of the biopotency of injected insulin, without causing any adverse effects, researchers reported here at the 66th Scientific Sessions of the American Diabetes Association.

Once-Weekly BYETTA (Exenatide) LAR Improves Glucose Control in Patients with Type 2 Diabetes Posted: Thursday, June 15, 2006

Reduces A1c by 2 points and average weight lose of 8 pounds in 15 weeks.

Ten Thousand Patients Using Levemir Insulin Show Improvements in BG Without Weight Gain Posted: Thursday, June 15, 2006

Levemir reduced mean A1C levels by 0.54 percent for type 1 and 0.89 percent for type 2 diabetes patients.

A Skin Patch for Insulin Delivery Posted: Thursday, June 15, 2006

The first results from an investigational transdermal insulin delivery system suggest that it is possible to deliver insulin through the skin.

Alternative to Carb Counting Posted: Thursday, June 15, 2006

Study shows an innovative mealtime insulin dosing algorithm provides alternative to carb counting for Type 2’s.

Increased Statin Dose Benefits Diabetics With Heart Disease Posted: Friday, June 09, 2006

The data suggest that the use of high-dose statin to achieve an LDL cholesterol level considerably lower than 100 mg/dL may be appropriate for patients with diabetes and coronary heart disease, irrespective of their initial LDL cholesterol level, age, duration of diabetes, or glycemic control.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.